The human microsomal epoxide hydrolase (EH) gene contains polymorphic alleles, which may be linked to increased risk for tobacco-related lung cancer. The purpose of this study is to screen new polymorphisms and determine whether these polymorphisms can be used to predict individual susceptibility to lung cancer. The polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis was used to screen for polymorphisms in the coding region of the EH gene. Eleven polymorphisms, including previously reported polymorphisms, were identified and the prevalence of these variants was assessed in at least 50 healthy Caucasians and African-Americans. Among the 11 polymorphisms, the prevalence of the amino acid-changing EH polymorphisms in codons 43, 113 and 139 was examined in 182 Caucasian incident cases with primary lung cancer, as well as in 365 frequency-matched controls to examine the role of EH polymorphisms in lung cancer risk. A significant increase in lung cancer risk was observed for predicted high EH activity genotypes (odds ratio (OR) 2.3, 95% confidence interval (CI) 1.2-4.3) as compared with low EH activity genotypes. This association was more pronounced among patients with lung adenocarcinoma (OR 4.7, 95% CI 1.7-13.1). These results suggest that the EH polymorphism plays an important role in lung cancer risk and is linked to tobacco smoke exposure.
Introduction
Genetic polymorphisms are associated with a number of genes that code for enzymes involved in the metabolic activation or detoxification of carcinogens. Large differences in the activities of carcinogen-metabolizing enzymes have been observed in many individuals, and it has been shown that enzyme activity-altering polymorphisms may influence individual cancer risk (McWilliams et al., 1995; Rebbeck, 1997; Lazarus and Park, 2000; London et al., 2000; Park et al., 2000) .
The epoxide hydrolase (EH) enzyme cleaves a range of alkene and arene oxides to form trans-dihydrodiols. For some polycyclic aromatic hydrocarbons (PAHs), including benzo(a)pyrene (BaP), the dihydrodiol derivatives are substrates for additional metabolism to more highly reactive and carcinogenic compounds. In two previous studies with a small number of subjects who had adverse reactions to anticonvulsant drugs (Gaedigk et al., 1994; Green et al., 1995) , several EH variants, including nonsynonymous polymorphism on codon 43, were identified, but none were associated with risk for hypersensitive reactions. Other studies have shown that two amino acidaltering polymorphisms located at codons 113 and 139 are associated with alterations in EH activity. The EH 113His variant is associated with a 40% decrease in EH activity while the EH 139Arg variant enhances enzyme activity by 25% via an increase in EH protein stability (Hassett et al., 1994) . These polymorphic alleles have previously been linked to risk change for colon (Harrison et al., 1999) , ovarian (Lancaster et al., 1996) and tobacco-related cancers, such as lung (Benhamou et al., 1998; Lin et al., 2000; London et al., 2000; To-Figueras et al., 2001; Wu et al., 2001; Yin et al., 2001; Zhao et al., 2002) and oral cavity (Park et al., 2003) . Together with the finding that EH is expressed in lung tissue (Omiecinski et al., 1993) , these data suggest that EH polymorphisms may play a role in lung cancer risk. The goals of the present study are to screen and identify EH polymorphisms in multiple racial groups (i.e. African-Americans and Caucasians) and determine whether they may be associated with increased risk for lung cancer.
Materials and methods

Study population for screening polymorphisms
For the identification of new EH polymorphisms in different racial groups, 40 Caucasians and 40 African-Americans from New York City were included. They were out-patients who were visiting an ear, nose and throat clinic for conditions unrelated to oral cancer. These subjects were recruited after an initial verbal screening to determine that they had no previous diagnosis of cancer.
To assess the prevalence of polymorphisms found in polymerase chain reaction (PCR) single strand conformation polymorphism (SSCP) analysis, subjects from the same area included at least 50 Caucasians and 50 African-Americans.
Study population for lung cancer case-control study
For the investigation of the roles of EH polymorphisms in lung cancer risk, all subjects were recruited from the H Lee Moffitt Cancer Center (Tampa, Florida, USA). All cases were patients diagnosed with primary lung cancer and were identified between 1999 and 2002. All cases were diagnosed within one year prior to recruitment into the study and were histologically confirmed by the Pathology Department at the H Lee Moffitt Cancer Center. Ninety-five per cent of case subjects who were asked to participate in the study consented.
We recruited control subjects at the Lifetime Cancer Screening Center affiliated with the H Lee Moffitt Cancer Center. All control subjects were recruited after an initial verbal screening to determine that they had no previous diagnosis of cancer, and none of the controls recruited into this study were diagnosed with any form of cancer or premalignancy after screening. The eligible pool of control subjects was restricted to those individuals with the same age at diagnosis ( ± 5 years), race, and sex as the case subjects. Eighty-five per cent of the control subjects who were asked to participate in the study consented.
For cases, buccal cell (n = 126) or blood (n = 56) samples collected at a follow-up examination were used for the analysis of polymorphic genotypes, while blood samples were collected for the analysis in controls (n = 365). Protocols involving the analysis of buccal cell and blood specimens were approved by the institutional review board at the H Lee Moffitt Cancer Center and informed consent was obtained from all subjects.
A questionnaire that contained questions on demographics and life-long smoking habits was administered to all study subjects. Tobacco use was categorized into pack-years for smokers of cigarettes (1 pack-year equals one pack of cigarettes per day for 1 year), cigars (1 packyear equals four cigars per day for 1 year), and pipe tobacco (1 pack-year equals five pipes per day for 1 year) according to the criteria described by Benhamou et al. (1986) . Study subjects who have smoked 100 or fewer cigarettes in their lifetime (the equivalent of 0.014 or fewer pack-years) were categorized as never-smokers.
PCR-SSCP and PCR-restriction fragment length polymorphism (PCR-RFLP) analysis of the EH gene Genomic DNA was isolated from oral buccal cells or blood from non-cancer controls by incubation overnight with proteinase K (0.1 mg/ml) in 1% sodium dodecyl sulfate at 501C and was extracted with phenol:chloroform and ethanol precipitation as previously described (Kabat et al., 1991) .
We utilized the PCR-SSCP analysis method to identify genetic polymorphisms in the EH gene. EH intronspecific sense and antisense primers, which are homologous to intron sequences immediately adjacent to EH coding exons and splice sites were used for all SSCP analysis. The primer sequences, annealing temperatures for PCR, and expected PCR fragment sizes are outlined in Table 1 . Screening for EH polymorphisms was performed by PCR amplification of genomic DNA from both African-Americans (n = 40) and Caucasians (n = 40), and SSCP analysis of amplified exons. Both Caucasians and African-Americans were screened to eliminate the possibility that ethnic-specific polymorphisms would be missed in this analysis. SSCP analysis of radio-labelled PCR products was performed as previously described (Park et al., 1997) . When the results of SSCP analysis suggested potential polymorphisms by shifted SSCP band patterns, the exact nature of the polymorphic EH sequence was elucidated directly from the shifted band on the SSCP gel by standard dideoxy sequencing (Sanger et al., 1977) . All DNA sequencing was performed at the Molecular Biology Core Facility located at the H Lee Moffitt Cancer Center. PCR-SSCP and sequencing analysis was repeated for all polymorphism-positive samples.
PCR-RFLP analyses were subsequently developed to examine the prevalence of identified EH polymorphisms. The prevalence of genetic polymorphisms in the EH gene was measured in at least 50 African-Americans and Caucasians, respectively (Table 2) . Genotyping assays for codons 43, 113 and 139 polymorphisms
One hundred and eighty-two lung cancer patients and 365 controls frequency-matched by age, gender and race were screened for the presence of the EH codon 43 polymorphism by a PCR-RFLP analysis. Exon 2 of EH gene was PCR-amplified using 100 ng EH intron 1 (5 0 -ggtcttcccctcatcttgc-3 0 ) and intron 2 (5 0cccggcccaaggtgcctt-3 0 )-specific primers to generate a 229bp fragment. The standard PCR was performed in a 50 ml reaction volume containing 50 ng of genomic DNA, 10 mmol/l Tris-HCl, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.2 mmol/l of each of the dNTPs, and 2.0 units of The genotyping assays for the EH codons 113 and 139 polymorphism were performed by PCR-RFLP analysis, described previously (Park et al., 2003) . This analysis was repeated for 10% of the specimens, and the selected PCR-amplified DNA samples (n = 20) were examined by dideoxy DNA sequencing (Sanger et al., 1977) to confirm EH genotyping results.
Statistical analysis
The risks of lung cancer in relation to EH genotypes were estimated using unconditional logistic regression to calculate ORs and 95% CIs. In this study, we designated the four possible EH alleles arising from the codons 113/ 139 polymorphism analysis as EH*1 (EH 113Tyr/139His ), EH*2 (EH 113Tyr/139Arg ), EH*3 (EH 113His/139His ) and EH*4 (EH 113His/139Arg ) ( Figure 1 ). Subjects were categorized into three groups based on the predicted activity of their EH genotype as described previously (Hassett et al., 1994) : the low EH activity genotypes (EH*3/EH*3 and EH*3/EH*4), intermediate EH activity genotypes (EH*1/EH*1, EH*1/EH*3, EH*2/EH*3 and EH*1/ EH*4,) and high EH activity genotypes (EH*1/EH*2, 
Results
PCR-SSCP analysis and identification of EH polymorphisms
Genomic DNA samples from 80 healthy subjects (40 Caucasians and 40 African-Americans) were subjected to SSCP-PCR analysis (Figure 2) . Table 2 shows the location and characters of 11 polymorphisms identified in the samples we analysed. Among the 11 polymorphisms detected, 5 non-synonymous, 5 synonymous and 1 SNP in intron 4 were found. Among the five non-synonymous polymorphisms, three of them were identified in previous studies (Gaedigk et al., 1994; Hassett et al., 1994; Green et al., 1995) . The allelic frequencies of codon 113 and 139 polymorphisms were similar to those observed in previous studies of both Caucasians and African-Americans (Hassett et al., 1994; Benhamou et al., 1998; Jourenkova-Mironova et al., 2000; London et al., 2000; Wu et al., 2001) . The allelic frequency for the codon 43 polymorphism was reported as 0.08 in a small study (Gaedigk et al., 1994) (n = 26), but we observed a significantly lower allelic frequency in our control population (0.01).
Differences in EH allelic frequencies were observed between Caucasians and African-American controls. Two polymorphisms, which are located in intron 4 (P < 0.02) and at codon 450 (P < 0.01) show significantly different allelic frequencies between two control groups. In addition, a significantly (P = 0.0019) lower frequency of the EH 139Arg allele was observed for Caucasians (0.18) as compared with African-Americans (0.31), while the EH 113His allelic frequency was significantly (P = 0.002) higher in Caucasians (0.33) than in African-Americans (0.20; Table 2 ).
EH genotypes and risk for lung cancer
A total of 182 Caucasian lung cancer patients and 365 frequency-matched control subjects were entered into this study. The mean ages of cases and controls were 62 and 65 and 42% of subjects were female (Table 3) . As expected, cases had a significantly higher level of cigarette consumption than controls (P = 0.019; Table 3 ).
To determine whether the EH variants contributed to increased lung cancer risk, we examined the prevalence of EH genotypes in lung cancer patients and compared them with control subjects. Due to the low allelic frequencies of codons 195 (0.006) and 382 (0.006) polymorphisms, these variants were not included in an estimation of their association with lung cancer risk. Significantly decreased risk for lung cancer was observed for subjects with the homozygous EH 113 His /113 His genotype (odds ratio (OR) 0.6, 95% confidence interval (CI) 0.33-0.96; Table 3 ). No significant association between the codons 43 and 139 polymorphism and lung cancer risk was observed, although the codon 43 data suggested a potential trend (P = 0.059) ( Table 3) .
Genotypes of individual subjects were determined by the combined data obtained from individual PCR-RFLP analysis of the codons 113 and 139 polymorphisms. The codon 43 polymorphism was not included for determining combined genotypes due to a low allelic frequency (0.01).
In controls, the prevalence of the EH 113His variant was 0.42, while the prevalence of the EH 139Arg variant was 0.19. The prevalence of these polymorphisms among controls followed the Hardy-Weinberg equilibrium.
When subjects were stratified based upon predicted EH activity genotypes, a significant increase in lung cancer risk was observed among subjects with high EH activity genotypes as compared with the low EH activity genotype (OR 2.3, 95% CI 1.2-4.3; Table 3 ). A significant association was found between predicted EH activity and lung cancer risk with a dose-effect relationship (trend test: P = 0.009).
To assess whether EH genotype-associated lung cancer risk was linked to specific lung cancer subtypes, cases were stratified according to tumour histological classifications. A significant risk increase was observed in the adenocarcinoma subtype of non-small cell lung cancer (high EH activity genotypes; OR 4.7, 95% CI 1.7-13.1) ( Table 4 ). Small cell lung carcinoma cases were not included from this analysis due to a low number of subjects.
To examine the relationship between EH genotypes and lung cancer risk by exposure to the environmental risk factor smoking, we stratified study subjects by predicted EH activity genotypes and smoking history (Table 5) . Ever-smokers (i.e. Z 100 cigarettes lifetime) were categorized into two groups based upon lifetime smoking history and divided at the median number of pack-years (46 pack-years) of smokers in the control population. The differences in risk associated with the EH genotypes were modified by smoking history. Due to a low number OR (95% CI) for intermediate c 2.4 (0.9-6.0) 1.1 (0.5-2.5) 1.0 (0.5-2.5) 1.3 (0.8-2.2) OR (95% CI) for high c 4.7 (1.7-13.1) 1.2 (0.4-3.7) 0.8 (0.2-3.1) 1.8 (0.9-3.6) a Numbers in parentheses refer to percentages. b Significant increase in predicted high-risk genotypes as determined by chi-squared trend test (P = 0.0001). c Adjusted for age, gender and smoking. (10) of lung cancer patients, we cannot assess the role of EH polymorphisms among never-smokers (data not shown). No association between EH genotypes and lung cancer risk was observed for heavy smokers ( > 46 packyears). However, non-significant risk increases were observed in light smokers ( r 46 pack-years) with both the intermediate (OR 2.3, 95% CI 0.9-5.6) and high (OR 2.6, 95% CI 0.9-7.7) EH activity genotypes (Table 5) . Among light smokers, a significant association was found between predicted EH activity and lung cancer risk with a dose-effect relationship (trend test: P < 0.05).
Discussion
Genetic polymorphisms in the genes coding for tobacco carcinogen-metabolizing enzymes may influence individual susceptibility to lung cancer. Although EH-induced hydrolysis is generally considered to represent a detoxification reaction because less toxic chemicals are usually produced, some trans-dihydrodiols generated from PAHs are substrates for additional metabolic changes to highly toxic, mutagenic and carcinogenic PAH diol epoxides. For example, EH converts BaP-7,8-epoxide to BaP-7, 8-dihydrodiol, which is a critical intermediate metabolite in the BaP carcinogenic pathway and is formed predominantly via oxidation by the CYP1A1 (Phillips, 1983) . Once formed, BaP-7,8-epoxide can either be detoxified by the glutathione S-transferase (GST) family of phase II enzymes or metabolized by EH to a diol intermediate , precursor to the ultimate carcinogenic BaP metabolite, BaP-7,8-diol-9,10-epoxide. Therefore, EH may play a significant role in the BaP-induced carcinogenic process.
Among several previous molecular epidemiological studies which have been performed on EH codons 113 and 139 polymorphisms, Lee et al. (2002) reported a significant decrease in lung cancer risk for the homozygous EH 113 His /113 His genotype and a stronger association in lung adenocarcinoma cases than other histological types in the pooled analysis. In this study, we observed a significant association between EH polymorphisms and lung cancer risk in Caucasians. This association is dose-dependent with significantly increased risk observed for subjects with predicted high EH activity genotypes. This association is more pronounced in patients with lung adenocarcinoma than for other histological types of the non-small cell lung cancers (Table 4 ). These results are consistent with a critical role for EH in tobacco-related cancer risk and in the metabolism of BaP-7,8-epoxide.
The effect of EH activity on lung cancer risk was modified by smoking level in the present study. Similar gene-environment interactions were also observed in a previous large EH epidemiological study (Zhou et al., 2001) . Although the difference was not statistically significant, a stronger association between EH genotypes and lung cancer was found among light smokers ( r 46 pack-years). This pattern is similar to that observed in previous studies examining polymorphic genotypes and cancer risk. The GSTM1 (0/0) (Nakachi et al., 1993; London et al., 1995) , the CYP1A1 exon 7 and Mspl polymorphisms (Nakachi et al., 1993; Ishibe et al., 1997) , and CYP2D6 polymorphisms (London et al., 1997) have all been shown to be associated with increased risk for lung cancer in light but not heavy smokers. It has been postulated that genetic variations in the ability to metabolize tobacco smoke carcinogens are most important in determining cancer risk at low levels of exposure, and may be less relevant at higher smoking doses where high levels of carcinogen exposure overwhelm polymorphism-induced differences in enzyme activity and/or expression (London et al., 1995) .
The data from this study present several previously unidentified polymorphisms in the EH gene. It has been reported that SSCP analysis can detect 80-90% of single nucleotide changes in DNA fragments smaller than 400 bp. However, a recent systematic analysis of the SSCP technique has shown that sensitivity varies with the size of the DNA fragment being analysed, with the optimal size being 150 bp (Sheffield et al., 1993) . The sensitivity of detecting a single base pair substitution was actually less than 60% when DNA fragments were about 400 bp. Since the PCR fragment sizes in the present study range from 149 bp for exon 7 to 308 bp for exon 4 (Table 1) , polymorphisms were likely detected with relatively high efficiency ( > 90%).
These are the first data that measure the prevalence of newly identified genetic polymorphisms in the EH gene in African-Americans and Caucasians. As expected, the prevalence of genetic polymorphisms found in African-Americans are often significantly different from those found in Caucasians. This data correspond with the fact that significant differences in prevalence were observed with EH codons 113 and 139 in different ethnic groups (London et al., 2000; Wu et al., 2001) . We investigated potential roles of codons 43, 113 and 139 non-synonymous polymorphisms among 11 polymorphisms identified from the screening process. Since there was not enough justification for investigating the roles of the other eight polymorphisms in lung cancer risk because they are not likely to affect activity of EH enzyme, the exact role was not assessed because of a lack of statistical power. Although we could not evaluate the exact role of codon 43 polymorphism due to a low allelic frequency (0.01), a marginal protective effect was observed (P = 0.059). Therefore, the codon 43 polymorphism is warranted for further investigation with a larger cohort study.
Another important smoking-related lung disease, chronic obstructive pulmonary disease (COPD), was linked with the EH codon 113 polymorphism (Yoshikawa et al., 2000; Sandford et al., 2001; Rodriguez et al., 2002) . However, these associations were not observed in other COPD epidemiological studies (Yim et al., 2000 (Yim et al., , 2002 Zhang et al., 2002) . Therefore, the role of EH polymorphisms in risk for pulmonary obstruction is not yet conclusive. Since this disease is associated with smoking and an increased 4-to 6-fold risk for lung cancer (Tockman et al., 1987) , it would be interesting to investigate the exact role of EH polymorphisms in lung cancer risk among subjects who have pulmonary obstructive disease.
In the present study, only the coding region of the EH gene had been analysed by SSCP analysis. Polymorphisms in the promoter or intronic region may also play important roles in lung cancer risk. Further studies examining these regions will be required to explore this possibility. A second limitation of this study is the fact that the number of case subjects recruited into this study was relatively small, especially for adenocarcinoma. Therefore, these results must be confirmed in larger studies especially for investigating a role of low EH activity genotypes in lung adenocarcinoma risk.
In conclusion, the present study has identified several polymorphisms in the coding region of the EH gene and observed that EH codon 43 polymorphism may decrease lung cancer risk and that predicted high activity EH genotypes are associated with increased risk for lung cancer.
